Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Autor: Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com., Sansregret L; Novartis BioMedical Research, Basel, Switzerland., Galli GG; Novartis BioMedical Research, Basel, Switzerland., Chène P; Novartis BioMedical Research, Basel, Switzerland., Wartmann M; Novartis BioMedical Research, Basel, Switzerland., Mourikis TP; Novartis BioMedical Research, Basel, Switzerland., Jaaks P; Novartis BioMedical Research, Basel, Switzerland., Baltschukat S; Novartis BioMedical Research, Basel, Switzerland., Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland., Bauer D; Novartis BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis BioMedical Research, Basel, Switzerland., Delaunay C; Novartis BioMedical Research, Basel, Switzerland., Estadieu C; Novartis BioMedical Research, Basel, Switzerland., Faris JE; Novartis BioMedical Research, Cambridge, MA, USA., Furet P; Novartis BioMedical Research, Basel, Switzerland., Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.; AstraZeneca, Oncology R&D, Cambridge, UK., Hueber A; Novartis BioMedical Research, Basel, Switzerland., Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland., Kodack DP; Novartis BioMedical Research, Cambridge, MA, USA., Mandon E; Novartis BioMedical Research, Basel, Switzerland., Martin T; Novartis BioMedical Research, Basel, Switzerland., Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland., Romanet V; Novartis BioMedical Research, Basel, Switzerland., Scheufler C; Novartis BioMedical Research, Basel, Switzerland., Sellner H; Novartis BioMedical Research, Basel, Switzerland., Stamm C; Novartis BioMedical Research, Basel, Switzerland., Sterker D; Novartis BioMedical Research, Basel, Switzerland., Tordella L; Novartis BioMedical Research, Basel, Switzerland., Hofmann F; Novartis BioMedical Research, Basel, Switzerland.; Pierre Fabre Group, R&D Medical Care, Toulouse, France., Soldermann N; Novartis BioMedical Research, Basel, Switzerland., Schmelzle T; Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.

Publikováno v: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1130.

Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice.

Autor: Casado-García A; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain., Isidro-Hernández M; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain., Oak N; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Mayado A; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Servicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Salamanca, Spain., Mann-Ran C; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Raboso-Gallego J; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain., Alemán-Arteaga S; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain., Buhles A; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Sterker D; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Sánchez EG; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain., Martínez-Cano J; Immune system development and function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Madrid, Spain., Blanco O; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain., Orfao A; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Servicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Salamanca, Spain., Alonso-López D; Bioinformatics Unit, Cancer Research Center (CSIC-USAL), Salamanca, Spain., De Las Rivas J; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Bioinformatics and Functional Genomics Research Group, Cancer Research Center (CSIC-USAL), Salamanca, Spain., Riesco S; Department of Pediatrics, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, Spain., Prieto-Matos P; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Department of Pediatrics, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, Spain., González-Murillo Á; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain., García Criado FJ; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain., García Cenador MB; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain., Radimerski T; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Ramírez-Orellana M; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain., Cobaleda C; Immune system development and function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Madrid, Spain., Yang JJ; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee., Vicente-Dueñas C; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Department of Pediatrics, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, Spain., Weiss A; Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland., Nichols KE; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Sánchez-García I; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Publikováno v: Cancer research [Cancer Res] 2022 Mar 15; Vol. 82 (6), pp. 1098-1109.

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.

Autor: Peng, Mei¹ (AUTHOR) meipeng@csu.edu.cn, Deng, Jun² (AUTHOR), Li, Xiangping¹ (AUTHOR) Xylxping@csu.edu.cn

Publikováno v: Molecular Cancer. 11/15/2024, Vol. 23 Issue 1, p1-17. 17p.

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.

Autor: Weiss A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Adler F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Buhles A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Stamm C; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Fairhurst RA; Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland., Kiffe M; Novartis Institutes for Biomedical Research, PK Sciences, Basel, Switzerland., Sterker D; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Centeleghe M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Wartmann M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Kinyamu-Akunda J; Novartis Institutes for Biomedical Research, Preclinical Safety, East Hanover New Jersey., Schadt HS; Novartis Institutes for Biomedical Research, Preclinical Safety, Basel, Switzerland., Couttet P; Novartis Institutes for Biomedical Research, Preclinical Safety, Basel, Switzerland., Wolf A; Novartis Institutes for Biomedical Research, Preclinical Safety, Basel, Switzerland., Wang Y; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, Massachusetts., Barzaghi-Rinaudo P; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Murakami M; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Kauffmann A; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Knoepfel T; Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland., Buschmann N; Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland., Leblanc C; Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland., Mah R; Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland., Furet P; Novartis Institutes for Biomedical Research, Global Discovery Chemistry, Basel, Switzerland., Blank J; Novartis Institutes for Biomedical Research, Chemical Biology and Therapeutics, Basel, Switzerland., Hofmann F; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland., Sellers WR; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, Massachusetts., Graus Porta D; Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland. diana.graus_porta@novartis.com.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Dec; Vol. 18 (12), pp. 2194-2206. Date of Electronic Publication: 2019 Aug 13.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Autor: Jeay S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ferretti S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland. stephane.ferretti@novartis.com francesco.hofmann@novartis.com., Holzer P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Fuchs J; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Chapeau EA; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Wartmann M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Sterker D; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Romanet V; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Murakami M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kerr G; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Durand EY; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Gaulis S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Cortes-Cros M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Ruetz S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Stachyra TM; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kallen J; Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland., Furet P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland., Würthner J; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Guerreiro N; PK Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland., Halilovic E; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Jullion A; Oncology Global Development, Basel, Switzerland., Kauffmann A; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Kuriakose E; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, East Hanover, New Jersey., Wiesmann M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Jensen MR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland., Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland. stephane.ferretti@novartis.com francesco.hofmann@novartis.com., Sellers WR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

Publikováno v: Cancer research [Cancer Res] 2018 Nov 01; Vol. 78 (21), pp. 6257-6267. Date of Electronic Publication: 2018 Aug 22.